Skip to content

Research at St Andrews

Dynamic modulation of phosphoprotein expression in ovarian cancer xenograft models

Research output: Contribution to journalArticle

Standard

Dynamic modulation of phosphoprotein expression in ovarian cancer xenograft models. / Koussounadis, Antonis; Langdon, Simon; Um, In Hwa; Kay, Charlene; Francis, Kyle; Harrison, David James; Smith, V Anne.

In: BMC Cancer, Vol. 16, 205, 10.03.2016.

Research output: Contribution to journalArticle

Harvard

Koussounadis, A, Langdon, S, Um, IH, Kay, C, Francis, K, Harrison, DJ & Smith, VA 2016, 'Dynamic modulation of phosphoprotein expression in ovarian cancer xenograft models' BMC Cancer, vol. 16, 205. https://doi.org/10.1186/s12885-016-2212-6

APA

Koussounadis, A., Langdon, S., Um, I. H., Kay, C., Francis, K., Harrison, D. J., & Smith, V. A. (2016). Dynamic modulation of phosphoprotein expression in ovarian cancer xenograft models. BMC Cancer, 16, [205]. https://doi.org/10.1186/s12885-016-2212-6

Vancouver

Koussounadis A, Langdon S, Um IH, Kay C, Francis K, Harrison DJ et al. Dynamic modulation of phosphoprotein expression in ovarian cancer xenograft models. BMC Cancer. 2016 Mar 10;16. 205. https://doi.org/10.1186/s12885-016-2212-6

Author

Koussounadis, Antonis ; Langdon, Simon ; Um, In Hwa ; Kay, Charlene ; Francis, Kyle ; Harrison, David James ; Smith, V Anne. / Dynamic modulation of phosphoprotein expression in ovarian cancer xenograft models. In: BMC Cancer. 2016 ; Vol. 16.

Bibtex - Download

@article{8cdfa9d1edd84a51826a322153c0af8b,
title = "Dynamic modulation of phosphoprotein expression in ovarian cancer xenograft models",
abstract = "Background: The dynamic changes that occur in protein expression after treatment of a cancer in vivo are poorly described. In this study we measure the effect of chemotherapy over time on the expression of a panel of proteins in ovarian cancer xenograft models. The objective was to identify phosphoprotein and other protein changes indicative of pathway activation that might link with drug response. Methods: Two xenograft models, platinum-responsive OV1002 and platinum-unresponsive HOX424, were used. Treatments were carboplatin and carboplatin-paclitaxel. Expression of 49 proteins over 14 days post treatment was measured by quantitative immunofluorescence and analysed by AQUA . Results: Carboplatin treatment in the platinum-sensitive OV1002 model triggered up-regulation of cell cycle, mTOR and DDR pathways, while at late time points WNT, invasion , EMT and MAPK pathways were modulated. Estrogen receptor-alpha (ESR1) and ERBB pathways were down-regulated early, within 24h from treatment administration. Combined carboplatin-paclitaxel treatment triggered a more extensive response in the OV1002 model modulating expression of 23 of 49 proteins. Therefore the cell cycle and DDR pathways showed similar or more pronounced changes than with carboplatin alone . In addition to expression of pS6 and pERK increasing, components of the AKT pathway were modulated with pAKT increasing while its regulator PTEN was down-regulated early. WNT signaling, EMT and invasion markers were modulated at later time points. Additional pathways were also observed with the NFκB and JAK/STAT pathways being up-regulated. ESR1 was down-regulated as was HER4, while further protein members of the ERB B pathway were upregulated late. By contrast, in the carboplatin-unresponsive HOX 424 xenograft, carboplatin only modulated expression of MLH1 while carboplatin-paclitaxel treatment modulated ESR1 and pMET.",
keywords = "Ovarian cancer, Carboplatin, Pacltaxel, Xenograft, Prognosis, Phosphoproteins",
author = "Antonis Koussounadis and Simon Langdon and Um, {In Hwa} and Charlene Kay and Kyle Francis and Harrison, {David James} and Smith, {V Anne}",
note = "The authors thank Medical Research Scotland and the Scottish Funding Council. This work was su pported by Medical Research Scotland [FRG353 to V.A.S.]; the FP7 -­‐ Directorate -­‐ General for Research and Innovation of the European Commission [EU HEALTH -­‐ F4 -­‐ 2012 -­‐ 305033 to Coordinating Action Systems Medicine -­‐ D.J.H.]; the Chief Scientist Office of Scotland [D.J.H.], the Scottish Funding Council [D.J.H. and S.P.L.]. Health Canada Scholarship (Indspire) [KEF], Scottish Overseas Research Student Award Scheme (University of Edinburgh)[KEF] and the Three Fires Award (Wikwemikong Board of Education)[KEF].",
year = "2016",
month = "3",
day = "10",
doi = "10.1186/s12885-016-2212-6",
language = "English",
volume = "16",
journal = "BMC Cancer",
issn = "1471-2407",
publisher = "BioMed Central",

}

RIS (suitable for import to EndNote) - Download

TY - JOUR

T1 - Dynamic modulation of phosphoprotein expression in ovarian cancer xenograft models

AU - Koussounadis, Antonis

AU - Langdon, Simon

AU - Um, In Hwa

AU - Kay, Charlene

AU - Francis, Kyle

AU - Harrison, David James

AU - Smith, V Anne

N1 - The authors thank Medical Research Scotland and the Scottish Funding Council. This work was su pported by Medical Research Scotland [FRG353 to V.A.S.]; the FP7 -­‐ Directorate -­‐ General for Research and Innovation of the European Commission [EU HEALTH -­‐ F4 -­‐ 2012 -­‐ 305033 to Coordinating Action Systems Medicine -­‐ D.J.H.]; the Chief Scientist Office of Scotland [D.J.H.], the Scottish Funding Council [D.J.H. and S.P.L.]. Health Canada Scholarship (Indspire) [KEF], Scottish Overseas Research Student Award Scheme (University of Edinburgh)[KEF] and the Three Fires Award (Wikwemikong Board of Education)[KEF].

PY - 2016/3/10

Y1 - 2016/3/10

N2 - Background: The dynamic changes that occur in protein expression after treatment of a cancer in vivo are poorly described. In this study we measure the effect of chemotherapy over time on the expression of a panel of proteins in ovarian cancer xenograft models. The objective was to identify phosphoprotein and other protein changes indicative of pathway activation that might link with drug response. Methods: Two xenograft models, platinum-responsive OV1002 and platinum-unresponsive HOX424, were used. Treatments were carboplatin and carboplatin-paclitaxel. Expression of 49 proteins over 14 days post treatment was measured by quantitative immunofluorescence and analysed by AQUA . Results: Carboplatin treatment in the platinum-sensitive OV1002 model triggered up-regulation of cell cycle, mTOR and DDR pathways, while at late time points WNT, invasion , EMT and MAPK pathways were modulated. Estrogen receptor-alpha (ESR1) and ERBB pathways were down-regulated early, within 24h from treatment administration. Combined carboplatin-paclitaxel treatment triggered a more extensive response in the OV1002 model modulating expression of 23 of 49 proteins. Therefore the cell cycle and DDR pathways showed similar or more pronounced changes than with carboplatin alone . In addition to expression of pS6 and pERK increasing, components of the AKT pathway were modulated with pAKT increasing while its regulator PTEN was down-regulated early. WNT signaling, EMT and invasion markers were modulated at later time points. Additional pathways were also observed with the NFκB and JAK/STAT pathways being up-regulated. ESR1 was down-regulated as was HER4, while further protein members of the ERB B pathway were upregulated late. By contrast, in the carboplatin-unresponsive HOX 424 xenograft, carboplatin only modulated expression of MLH1 while carboplatin-paclitaxel treatment modulated ESR1 and pMET.

AB - Background: The dynamic changes that occur in protein expression after treatment of a cancer in vivo are poorly described. In this study we measure the effect of chemotherapy over time on the expression of a panel of proteins in ovarian cancer xenograft models. The objective was to identify phosphoprotein and other protein changes indicative of pathway activation that might link with drug response. Methods: Two xenograft models, platinum-responsive OV1002 and platinum-unresponsive HOX424, were used. Treatments were carboplatin and carboplatin-paclitaxel. Expression of 49 proteins over 14 days post treatment was measured by quantitative immunofluorescence and analysed by AQUA . Results: Carboplatin treatment in the platinum-sensitive OV1002 model triggered up-regulation of cell cycle, mTOR and DDR pathways, while at late time points WNT, invasion , EMT and MAPK pathways were modulated. Estrogen receptor-alpha (ESR1) and ERBB pathways were down-regulated early, within 24h from treatment administration. Combined carboplatin-paclitaxel treatment triggered a more extensive response in the OV1002 model modulating expression of 23 of 49 proteins. Therefore the cell cycle and DDR pathways showed similar or more pronounced changes than with carboplatin alone . In addition to expression of pS6 and pERK increasing, components of the AKT pathway were modulated with pAKT increasing while its regulator PTEN was down-regulated early. WNT signaling, EMT and invasion markers were modulated at later time points. Additional pathways were also observed with the NFκB and JAK/STAT pathways being up-regulated. ESR1 was down-regulated as was HER4, while further protein members of the ERB B pathway were upregulated late. By contrast, in the carboplatin-unresponsive HOX 424 xenograft, carboplatin only modulated expression of MLH1 while carboplatin-paclitaxel treatment modulated ESR1 and pMET.

KW - Ovarian cancer

KW - Carboplatin

KW - Pacltaxel

KW - Xenograft

KW - Prognosis

KW - Phosphoproteins

U2 - 10.1186/s12885-016-2212-6

DO - 10.1186/s12885-016-2212-6

M3 - Article

VL - 16

JO - BMC Cancer

T2 - BMC Cancer

JF - BMC Cancer

SN - 1471-2407

M1 - 205

ER -

Related by author

  1. Relationship between differentially expressed mRNA and mRNA-protein correlations in a xenograft model system

    Koussounadis, A., Langdon, S., Um, I. H., Harrison, D. J. & Smith, V. A., 8 Jun 2015, In : Scientific Reports. 5, 9 p., 10775.

    Research output: Contribution to journalArticle

  2. Genome-scale CRISPR/Cas9 screen determines factors modulating sensitivity to ProTide NUC-1031

    Sarr, A., Bré, J., Um, I. H., Chan, T. H., Mullen, P., Harrison, D. J. & Reynolds, P. A., 21 May 2019, In : Scientific Reports. 9, 13 p., 7643.

    Research output: Contribution to journalArticle

  3. Multi-scale genomic, transcriptomic and proteomic analysis of colorectal cancer cell lines to identify novel biomarkers

    Briffa, R., Um, I. H., Faratian, D., Zhou, Y., Turnbull, A. K., Langdon, S. P. & Harrison, D. J., 17 Dec 2015, In : PLoS One. 10, 12, 29 p., e0144708.

    Research output: Contribution to journalArticle

  4. The role of HDAC2 in chromatin remodelling and response to chemotherapy in ovarian cancer

    Huang, R., Langdon, S. P., Tse, M., Mullen, P., Um, I. H., Faratian, D. & Harrison, D. J., 14 Dec 2015, In : Oncotarget. 7, 4, p. 4695-4711 17 p.

    Research output: Contribution to journalArticle

  5. Novel Monte Carlo approach quantifies data assemblage utility and reveals power of integrating molecular and clinical information for cancer prognosis

    Verleyen, W., Langdon, S. P., Faratian, D., Harrison, D. J. & Smith, V. A., 27 Oct 2015, In : Scientific Reports. 5, 7 p., 15563.

    Research output: Contribution to journalArticle

Related by journal

  1. Fear of cancer recurrence trajectory during radiation treatment and follow-up into survivorship of patients with breast cancer

    Yang, Y., Cameron, J., Bedi, C. & Humphris, G., 20 Oct 2018, In : BMC Cancer. 18, 9 p., 1002.

    Research output: Contribution to journalArticle

  2. Improving quality of life through the routine use of the patient concerns inventory for head and neck cancer patients: a cluster preference randomized controlled trial

    Rogers, S. N., Lowe, D., Lowies, C., Yeo, S. T., Allmark, C., Mcavery, D., Humphris, G. M., Flavel, R., Semple, C., Thomas, S. J. & Kanatas, A., 18 Apr 2018, In : BMC Cancer. 18, 10 p., 444.

    Research output: Contribution to journalArticle

  3. Serum and blood based biomarkers for lung cancer screening: a systematic review

    Chu, G. C. W., Lazare, K. & Sullivan, F., 13 Feb 2018, In : BMC Cancer. 18, 6 p., 181.

    Research output: Contribution to journalReview article

  4. A systematic search strategy identifies cubilin as independent prognostic marker for renal cell carcinoma

    Gremel, G., Djureinovic, D., Niinivirta, M., Laird, A., Ljungqvist, O., Johannesson, H., Bergman, J., Edqvist, P-H., Navani, S., Khan, N., Patil, T., Sivertsson, Å., Uhlén, M., Harrison, D. J., Ullenhag, G. J., Stewart, G. D. & Pontén, F., 4 Jan 2017, In : BMC Cancer. 17, 9 p., 9.

    Research output: Contribution to journalArticle

ID: 241226118